Skip to main content

Taggar

andningsvägar

cancer

diabetes

forskning & utveckling

hjärta/kärl

ledning

mage/tarm

neurovetenskap

AstraZeneca 234 forskning & utveckling 113 cancer 112 hjärta/kärl 88 diabetes 63 andningsvägar 30 mage/tarm 14 neurovetenskap 11 FDA 10 onkologi 8 delårsrapport 8 astma 7 forskning 7 infektion 7 seroquel 7 akut kranskärlssjudom 6 medimmune 6 Observationsstudie 6 vandetanib 5 egfr-testning 5 bokslutsrapport 5 influensavaccin 5 forxiga 5 naloxegol 5 ledning 5 motavizumab 5 Tagrisso 5 RWE 5 ledgångsreumatism 4 antibiotika 4 seroquel xr 4 fostamatinib 4 karolinska institutet 4 anders ekblom 4 olaparib 4 lungcancer 4 bristol-myers squibb 4 fluenz 4 tc-5214 4 vimovo 3 kroniskt obstruktiv lungsjukdom 3 CVD-REAL 3 gefitinib 3 pathos 3 produkt 3 subvention 3 slusg 3 crestor® 3 osimertinib 3 astra tech 3 egentlig depression 3 antibiotikaresistens 3 styrelsen 3 japan 3 selumetinib 3 läkemedelsförmånen 2 registerstudie 2 typ2diabetes 2 byetta 2 astrazenca 2 slusg stipendium 2 ardea biosciences 2 recentin 2 klopidogrel 2 patenttvist 2 entocort 2 tyskland 2 confirm 2 opioider 2 seroquel xl 2 axanum 2 kvartalsrapport 2 Brilique 2 seroquel xr (quetiapin fumarat) 2 återfall 2 ticagrelor 2 mdd 2 epanova 2 acalabrutinib 2 Real World evidence 2 fulvestrant 2 targacept 2 caprelsa 2 almedalen 2 individanpassad behandling 2 bydureon 2 samarbete 2 saturn 2 kina 2 smärta 2 esc 2 life science 2 benralizumab 2 päivi tolstoy 1 ceftarolinfosamil 1 EGFR 1 kronisk smärta 1 antaros 1 fas 3-studie 1 sekundärprevention 1 arbetsmarknadsdagar 1 motivationsstöd 1 Lynparza 1 ovarian cancer 1 bakterier 1 kol 1 astrazeneca lund 1 forskarstipendium 1 stipendier 1 alzheimers 1 non-small cell lung cancer 1 konkurrenskraften 1 usa 1 citizen petitions 1 e-brilique 1 jan lundberg 1 denosumab 1 noc) 1 kanadensiska hälsovårdsministeriet 1 subventioner 1 cancerregister 1 hälsoekonomi 1 kranskärlsjukdom 1 mobiltelefonapplikation 1 pfizer 1 metabola sjukdomar 1 cediranib 1 generiska läkemedel 1 skatteärende 1 cardiologföreningen 1 vnr 1 glp-1 agonister 1 SUPPORT-studien 1 certriad 1 monoterapi 1 hormonresistent 1 scilifelab 1 livskvalitet lungcancer 1 david brennan 1 karolinska universitetssjukhuset 1 astma/kol 1 arimidex 1 patientstöd 1 artros 1 per alfredsson 1 faslodex (fulvestrant) 1 mobil-app 1 pegasus-timi 1 delårsrapport januari-september 2011 1 hjärinfarkt 1 hjärtinfarkt 1 klinisk forsk 1 egfr positiv 1 advaxis 1 QTERN 1 medicon village 1 årsredovisning 2010 1 nda 1 forskare 1 merck-avtal 1 alzheimers sjukdom 1 the medicines company 1 brodalumab 1 complete response letter (crl) 1 avastin 1 xigduo 1 magnus björsne 1 mölndal 1 torrent pharma 1 psoriasis 1 NSCLC 1 forskarkarriärer 1 amend 1 oic 1 äggstockscancer 1 budesonid 1 jupiter-studien 1 jupiter 1 merck 1 viktökning 1 apollo 1 debatt 1 nya läkemedel 1 iressa 1 renaissance 5 1 gensekvensering 1 fluenz tetra 1 delårsrapport januari - mars 1 innovation 1 sjukhusinfektioner 1 säsongsinfluencavaccin 1 yngre forskare 1 antibiotikum 1 produktionschef 1 världsdiabetesdagen 2014 1 saxagliptin 1 halvårsrapport 1 gener 1 patientundersökning 1 healthy heart africa 1 biokemiska markörer 1 egfr-muterad 1 läkemedel 1 hha 1 flumist 1 tlv 1 skl 1 durvalumab 1 formuleringspatent 1 målstyrt läkemedel 1 kombiglyze xr 1 mikael agaton 1 ny indikation 1 pegasus 1 generiskt esomeprazolmagnesium 1 sponsring 1 eurika 1 aks 1 asco 1 zactima (vandetanib) 1 anläggningar 1 DAISY 1 avancerad hormonkänslig bröstcancer 1 lund 1 syntetisk kemi 1 r&d 1 nässprayvaccin 1 förstoppning 1 årsredovisning 2011 1 immunoterapier 1 tre strategiska centra 1 moventig 1 mcrc 1 kolorektalcancer 1 ldl-c 1 dow jones sustainability index 1 inflammation 1 nytt läkemedel lungcancer 1 hjärt-och kärlsjukdom 1 pluto-studien 1 patologi 1 first studien 1 egfr mutation 1 läkemedelstillverkning 1 hans andersson 1 lif 1 ordnat införande Almedalen 1 hypoglykemi 1 stöd 1 citizens petition 1 hälsoekonomiska data 1 anastrozol 1 varumärkta generika 1 ämnesomsättningssjukdomar (emdac) 1 vaccinet 1 roger henriksson 1 bröstcancer utmärkelse 2012 1 hudinfektioner 1 myalept 1 pressmaterial 1 azd9773 1 sumitomo 1 vimovotm 1 bevacizumab 1 Uppsala Clinical Research Center 1 opioidbehandling 1 lipodystrofi 1 CVD-REAL Nordic 1 produktionsanläggning 1 jonas bergh 1 bioventurehub 1 blodförgiftning 1 läkemedelsforskning 1 max planck institute 1 corporate 1 h1n1 1 per hamid ghatan 1 lungcancersymtom 1 caz-avi 1 tonårshjärnan 1 telekonferens 1 biohub 1 antidepressiva läkemedel 1 farxiga 1 läkemedelsforskningen 1 behandling lungcancer 1 toprol-xl 1 invasiv behandling 1 kyntheum 1 non-small-cell lungcancer 1 blodsockerfall 1 savor 1 gonorré 1 Imfinzi 1 prismodell 1 atac 1 kvalitetsregister 1 elisabeth björk 1 prevention 1 influensa 1 zinforo 1 translationell 1 leif johansson 1 quetiapin fumarat 1 patient websida 1 sepsis 1 mjukdelsinfektioner 1 exacerbationer 1 nytt läkemedel mot lungcancer 1 eu 1 hjärtkärlhälsa 1 pozen 1 SvFP 1 ämnesomsättningssjukdomar 1 nikotinkanalsblockerare 1 stemi 1 säsongsinfluensavaccin för barn som nässpray 1 metreleptin 1 årets kvinnliga ledare 1 collaboration 1 depression 1 nsaid 1 american college of rheumatology 1 sustainable brands 2011 1 cytofab 1 kvadrivalent 1 UCR 1 Zavicefta 1 rosuvastatinkalcium 1 amylin 1 registreringsansökan 1 diagnostik 1 rosuvastatin 1 hyperkolesterolemi 1 schizofreni 1 amylin pharmaceuticals 1 pa 1 norge 1 grymt fett en filmserie om tonårshjärnan 1 sjukhussjuka 1 remissvar prismodell 1 illumina 1 pascal soriot 1 halvårsresultat 1 ipass 1 mdr-tb 1 right honourable baroness shriti vadera 1 pet 1 renaissance 4 1 akuta koronara syndrom 1 södertälje 1 strategiska centra 1 hållbar utveckling 1 nktr-118 1 gikt 1 socialminister 1 opioidorsakad 1 ann cairns 1 sommarforskarskola 1 svenska lungcancerstudiegruppen 1 beslut 1 2009 annual scientific meeting in philadelphia 1 tobias ankner 1 bioläkemedel 1 bypass 1 skelettmetastaser 1 non-executive director 1 lesinurad 1 blogg 1 internationell konkurrens 1 exenatide 1 stroke 1 patent 1 barninfluensavaccin 1 osimertinub 1 influensanässpray 1 u.s. food and drug administration (fda) 1 zibotentan 1 berzeliussamlingen 1 karin norlén 1 kemi 1 pris läkemedel 1 styrelseordförande 1 produktion 1 typ 2-diabetes 1 blodsockerkontroll 1 mrsa 1 stipendieprogram 1 den amerikanska läkemedelsmyndigheten 1 dapagliflozin 1 apotex inc (notice of compliance 1 lesinurab 1 forsknings - och utvecklingscentra 1 komboglyze 1 grymt fett 1 avancerad bröstcancer 1 forskningsportfölj 1 högkostnadsskyddet 1 kastrationsresistent 1 moderna therapeutics 1 journal of clinical oncology 1 Visa alla taggar

Senaste nytt

Risk of repeat heart attack twice as likely from occlusions in arteries that did not cause initial event

Risk of repeat heart attack twice as likely from occlusions in arteries that did not cause initial event

Pressmeddelanden   •   Jan 16, 2018 16:42 CET

AstraZeneca announced today the publication of a new analysis from an ongoing real-world quality registry that suggests the risk of experiencing a repeat heart attack (also known as a myocardial infarction or MI) from occlusions in non-stentedarteries is twice as high as the risk stemming from the initially stented artery following a first heart attack.

Lynparza approved by US FDA in germline BRCA-mutated   metastatic breast cancer

Lynparza approved by US FDA in germline BRCA-mutated metastatic breast cancer

Pressmeddelanden   •   Jan 12, 2018 17:20 CET

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved Lynparza (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm),

Fasenra receives EU approval for severe  eosinophilic asthma

Fasenra receives EU approval for severe eosinophilic asthma

Pressmeddelanden   •   Jan 10, 2018 16:28 CET

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Commission (EC) has approved Fasenra (benralizumab) as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists.

Media no image
Media no image

AstraZeneca to highlight its commitment to blood cancers at the 2017 American Society of Hematology Annual Meeting

Pressmeddelanden   •   Dec 06, 2017 08:02 CET

AstraZeneca, along with Acerta Pharma, its haematology research and development centre of excellence, and MedImmune, its global biologics research and development arm, will highlight significant progress in blood cancer research at the 59th 2017 American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA

Tudorza reduces exacerbations and demonstrates cardiovascular safety in COPD patients

Tudorza reduces exacerbations and demonstrates cardiovascular safety in COPD patients

Pressmeddelanden   •   Dec 04, 2017 08:04 CET

AstraZeneca today announced positive top-line results of the Phase IV ASCENT trial for Tudorza Pressair (aclidinium bromide 400 μg, twice-daily), a long-acting muscarinic antagonist (LAMA), in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), with a history of cardiovascular disease and/or significant cardiovascular risk factors.

The European Medicines Agency accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer

The European Medicines Agency accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer

Pressmeddelanden   •   Nov 28, 2017 08:15 CET

AstraZeneca today announced that the European Medicines Agency has accepted a variation to the Marketing Authorisation Application (MAAv) for Tagrisso (osimertinib),

AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China

AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China

Pressmeddelanden   •   Nov 27, 2017 08:17 CET

AstraZeneca today announced a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China to discover, develop and commercialise potential new medicines to help meet unmet needs globally, and to bring innovative new medicines to patients in China faster.

AstraZeneca makes regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer in Japan

AstraZeneca makes regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer in Japan

Pressmeddelanden   •   Nov 27, 2017 08:04 CET

AstraZeneca today announced the submission of a supplemental new drug application (sNDA) to Japan’s Pharmaceuticals and Medical Devices Agency for the use of Tagrisso (osimertinib).

Media no image
Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma

Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma

Pressmeddelanden   •   Nov 15, 2017 08:01 CET

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

Benralizumab får positivt CHMP-utlåtande i EU  för behandling av svår, okontrollerad eosinofil astma
AstraZeneca PLC:s resultatrapport för första nio månader och tredje kvartalet 2017
AstraZeneca shares scientific updates from its extensive cardiovascular, renal and metabolic diseases (CVMD) portfolio at AHA 2017

AstraZeneca shares scientific updates from its extensive cardiovascular, renal and metabolic diseases (CVMD) portfolio at AHA 2017

Pressmeddelanden   •   Nov 08, 2017 08:02 CET

AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining its scientific focus on cardiovascular, renal and metabolic diseases (CVMD) with 28 presentations, including two late-breaking trials, at the American Heart Association (AHA) Scientific Sessions, November 11-15, 2017 in Anaheim, California.

AstraZeneca provides update on tralokinumab Phase III Programme in severe, uncontrolled asthma
FDA godkänner AstraZenecas Calquence (acalabrutinib) för vuxna patienter med tidigare behandlad mantelcellslymfom

FDA godkänner AstraZenecas Calquence (acalabrutinib) för vuxna patienter med tidigare behandlad mantelcellslymfom

Pressmeddelanden   •   Okt 31, 2017 18:23 CET

AstraZeneca och dess FoU-center för hematologi, Acerta Pharma, meddelar idag att den amerikanska läkemedelsmyndigheten FDA har godkänt Calquence(acalabrutinib) inom ramen för så kallat ”påskyndat godkännande” Calquence är en tyrosinkinashämmare och indikationen gäller behandling av vuxna patienter med mantelcellslymfom (MCL) som har fått minst en tidigare behandling. 1

 AstraZeneca and Incyte enter clinical trial collaboration in early lung cancer

AstraZeneca and Incyte enter clinical trial collaboration in early lung cancer

Pressmeddelanden   •   Okt 31, 2017 08:14 CET

​AstraZeneca and MedImmune, its global biologics research and development arm, today announced the expansion of their clinical collaboration with Incyte Corporation.

AstraZeneca and MSD rapidly advance Lynparza in Japan with a second regulatory submission

AstraZeneca and MSD rapidly advance Lynparza in Japan with a second regulatory submission

Pressmeddelanden   •   Okt 23, 2017 08:14 CEST

AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US today announced that they have submitted a new drug application (NDA) to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Lynparza(olaparib) tablets in unresectable or recurrent BRCA-mutated breast cancer, with a decision expected in the second half of 2018.

US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes

US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes

Pressmeddelanden   •   Okt 23, 2017 08:06 CEST

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of Bydureon in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise

US FDA accepts regulatory submission for  Lynparza in metastatic breast cancer and  grants priority review

US FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants priority review

Pressmeddelanden   •   Okt 18, 2017 08:03 CEST

Lynparza has the potential to offer a new treatment option for patients with germline BRCA-mutated, HER2-negative metastatic breast cancer Regulatory submission acceptance is first for a PARP inhibitor beyond ovarian cancer